MEDIAN Technologies to participate in 2012 ASCO annual conference

MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software developer and service provider for oncology clinical trials, announced today its participation in the 2012 ASCO annual conference, to be held next June 1-5, in Chicago, IL, USA.

During ASCO, the world's premier oncology conference, representatives from MEDIAN will be available to discuss their abstract, 'Reliability of Imaging Biomarkers for Response Assessment in Advanced Lung Cancer: Influence of Expertise and Automation.' MEDIAN's scientific and business development teams will be present at booth 22089 to give demonstrations of their Lesion Management Solutions (LMS) software.

ASCO's annual meeting will be the occasion for MEDIAN Technologies to officially announce the operational launch of their alliance with Quintiles, the world's leading biopharmaceutical services organization, to the biopharmaceutical industry and the clinical investigator community.

The Oncology focused alliance agreement between MEDIAN Technologies and Quintiles is designed to provide biopharma customers and clinical investigators with better quality data, increased productivity, faster go/no-go decisions, and, ultimately, more robust regulatory submissions.

"For the past three months we have been creating a highly efficient, integrated operational alliance to deliver what we believe is a truly differentiated medical imaging service to the biopharma industry," said Fredrik Brag, MEDIAN's Chief Executive Officer. "Working with Quintiles broadens the scope of clinical trials using our imaging technology to the global level, resulting in better outcomes for today's patients."

Today, the ability to gather, share, interpret and sort through medical image data is at the very heart of how cancer therapies and potential cures are being developed and evaluated. But the inherent complexity of managing imaging-based trials across multiple sites introduces many complex challenges, some of which threaten the value of imaging. MEDIAN has set out to change the paradigm for imaging in oncology trials by applying new technology-based solutions to frequently-observed issues related to image interpretation and management: most notably, high rates of variability in data interpretation and a rising complexity in imaging workflows.